Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Histamine H3 Receptor Double Nickase Plasmid (h): sc-402473-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Histamine H3 Receptor Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Histamine H3 Receptor Double Nickase Plasmid (h) and Histamine H3 Receptor Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting HRH3. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Histamine H3 Receptor Antibody (D-5): sc-390140
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Histamine H3 Receptor Double Nickase Plasmid (h) | sc-402473-NIC | 20 µg | $410.00 |
HRH3 encodes the histamine H3 receptor, a Gi/o-coupled GPCR enriched in the central nervous system that functions primarily as a presynaptic autoreceptor and heteroreceptor to regulate neurotransmitter release. Upon histamine binding, HRH3 signaling inhibits adenylyl cyclase to reduce cAMP/PKA activity and modulates ion channel conductance and downstream MAPK/ERK pathways, shaping neuronal excitability and synaptic plasticity. Through control of histaminergic tone and cross-talk with dopaminergic, cholinergic, and noradrenergic circuits, HRH3 contributes to sleep–wake regulation, cognition, and appetite-related neurobiology. Altered HRH3 expression or signaling has been investigated in the context of neurological and neuropsychiatric disease mechanisms, supporting its utility as a target for pathway and circuit-level research.
Histamine H3 Receptor Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the HRH3 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within HRH3. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt HRH3 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of HRH3-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.